

# AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING

## LONG-TERM GUIDANCE

2022 - 2030

Revenues

Mid-single digit  
CAGR

Non-GAAP

Operating Margin  
*% of product sales*

Approximately 50%

Non-GAAP EPS

High-single to low  
double-digit CAGR

AMGEN

## 2022 GUIDANCE

2022 GUIDANCE

Revenues

\$25.4B–\$26.5B

Non-GAAP EPS

\$17.00–\$18.00

Non-GAAP Tax Rate

13.0%–14.0%

Capital  
Expenditures

~ \$950M

AMGEN

Provided Feb. 8, 2022, as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. For non-GAAP measures, see the reconciliations accompanying the press release from which this embedded image was derived ("Amgen Provides Long-Term Guidance Through 2030 During Business Review Meeting," Feb. 8, 2022).